# Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

> **NCT03099499** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** ONC201

## Key facts

- **NCT ID:** NCT03099499
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-08
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-09
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099499, "Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03099499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*